Ebola Treatment Trial Expands in North Kivu Amid Rising Fatalities

A clinical trial of an experimental Ebola therapeutic is now underway in the North Kivu province of the Democratic Republic of Congo (DRC), as the country records a steady increase in deaths from the latest outbreak. The trial, coordinated by the World Health Organization (WHO) and the DRC Ministry of Health, involves administering the monoclonal antibody drug mAb114 to patients at two treatment centers in the towns of Beni and Butembo. Health officials say the drug, which has shown promise in previous Ebola outbreaks, will be given alongside standard supportive care to all confirmed cases admitted to the facilities.

Since the outbreak was declared in early August, the Ministry of Health has reported 124 laboratory‑confirmed Ebola cases, including 84 deaths, resulting in a case‑fatality ratio of roughly 68 percent. The majority of infections have been traced to the eastern provinces of North Kivu and Ituri, where armed groups and displaced populations create conditions that hamper surveillance, contact tracing and safe burial practices. The trial aims to assess whether mAb114 can reduce mortality compared with the historical baseline of supportive care alone.

The WHO’s Emergency Committee approved the trial after reviewing data from the 2018‑2020 outbreak in the DRC, where mAb114 achieved a 30 percent reduction in deaths in a randomized controlled study. The current protocol enrolls up to 150 patients, with random assignment to receive either the monoclonal antibody infusion or the standard of care. Researchers will monitor viral load, organ function and survival over a 28‑day period, and will also collect data on adverse events to evaluate safety in the field setting.

“Providing access to promising therapeutics is essential while we continue to strengthen routine case management,” said Dr. Jean‑Claude Kambale, the DRC’s national Ebola response coordinator. “The trial does not replace the need for rapid diagnosis, isolation and community engagement, but it adds a potentially life‑saving tool to our response arsenal.” He added that the trial’s results could inform future WHO recommendations for Ebola treatment in low‑resource environments.

The expansion of the trial coincides with intensified efforts to contain the outbreak. Over the past month, response teams have vaccinated more than 12,000 frontline workers and contacts with the rVSV‑ZEBOV vaccine, and have deployed additional rapid‑response teams to trace contacts in hard‑to‑reach villages. However, security incidents have hampered operations; in early September, an armed group attacked a health post in the village of Kanyabayonga, forcing staff to withdraw temporarily.

The ongoing conflict in eastern DRC provides the broader context for the health emergency. Since 1998, the region has been plagued by armed clashes involving government forces, rebel militias and foreign mercenaries, primarily over control of mineral resources such as coltan and gold. The violence has displaced millions, disrupted health infrastructure and created a humanitarian crisis that complicates disease surveillance. In recent years, the United Nations peacekeeping mission (MONUSCO) has struggled to protect civilians, while periodic ceasefires have failed to produce lasting stability.

Ebola outbreaks have historically exploited these vulnerabilities. The 2018‑2020 epidemic, which also unfolded in North Kivu and Ituri, resulted in 2,287 cases and 1,506 deaths, making it the second‑largest Ebola outbreak on record. That crisis highlighted the challenges of delivering care in conflict zones, where health workers faced threats, road blockades and community mistrust. The current outbreak, though smaller in scale, has reignited concerns about the capacity of the DRC’s health system to respond effectively under such conditions.

International partners are closely watching the trial’s progress. The United Nations Children’s Fund (UNICEF) and the International Federation of Red Cross and Red Crescent Societies (IFRC) have supplied personal protective equipment and logistical support to the treatment centers. Meanwhile, the Global Fund has pledged additional financing to bolster laboratory capacity for rapid Ebola testing, aiming to reduce the time between symptom onset and confirmation from an average of five days to under two.

Experts caution that while the monoclonal antibody could lower mortality, it is not a substitute for comprehensive outbreak control measures. Dr. Sarah Mwangi, an epidemiologist with the African Centres for Disease Control and Prevention, emphasized that “vaccination, robust contact tracing, safe burial practices and community trust remain the cornerstone of any Ebola response.” She noted that the trial’s findings will be most valuable if integrated into a coordinated strategy that addresses both medical and socio‑political determinants of disease spread.

The trial is expected to conclude by early 2027, with interim analyses scheduled for six‑month intervals. Results will be shared with the WHO’s Emergency Use Assessment and Listing (EUAL) Committee, which could lead to broader approval of mAb114 for use in future outbreaks. If the drug proves effective, it may become the first widely available therapeutic for Ebola in low‑resource settings, potentially reshaping global health policy on emerging infectious diseases.

For now, the immediate priority remains to treat patients, protect health workers and prevent further transmission in a region where conflict and disease intersect. The trial represents a concerted effort by national authorities and the international community to bring advanced medical interventions to a population that has long endured the dual burdens of war and epidemic.